PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-16.72%
Both companies show declining cash positions (-16.72% vs TRVN's -23.12%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-16.72%
Cash + STI yoy 1.25-1.5x TRVN's -11.48%. Bruce Berkowitz would check if the firm is preparing for expansions or simply hoarding.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Higher Other Current Assets Growth compared to TRVN's zero value, indicating worse performance.
-19.08%
≥ 1.5x TRVN's -10.28%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
-14.24%
Below half TRVN's 3.49%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-9.11%
Below half of TRVN's 1.63%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.02%
≥ 1.5x TRVN's -10.04%. David Dodd notes a larger balance sheet expansion. Confirm it's not overleveraged.
-4.20%
Less than half of TRVN's -46.14%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
76.87%
Less than half of TRVN's -98.02%. David Dodd sees fewer expansions in other current obligations.
18.79%
Less than half of TRVN's -49.90%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
18.79%
Less than half of TRVN's -0.65%. David Dodd sees far fewer liability expansions relative to competitor.
2.42%
1.25-1.5x TRVN's 1.79%. Martin Whitman sees potential dilution risk vs. competitor approach.
-5.90%
0.75-0.9x TRVN's -7.25%. Bill Ackman questions if competitor reinvests profits more robustly.
-12.27%
Less than half of TRVN's -2550.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-28.51%
≥ 1.5x TRVN's -14.36%. David Dodd sees stronger capital base growth than competitor.
-19.02%
≥ 1.5x TRVN's -10.04%. David Dodd sees faster overall balance sheet growth than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
16.72%
Less than half of TRVN's 256.12%. David Dodd sees better deleveraging or stronger cash buildup than competitor.